Cargando…

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism

The aim of this study was to 1) investigate the effects of 27 CYP3A4 variants on the metabolism of osimertinib and 2) study the interactions between osimertinib and others as well as the underlying mechanism. A recombinant human CYP3A4 enzymatic incubation system was developed and employed to determ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Nanyong, Zhang, Xiaodan, Hu, Xiaoqin, Kong, Qihui, Cai, Jianping, Hu, Guoxin, Qian, Jianchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960255/ https://www.ncbi.nlm.nih.gov/pubmed/35359868 http://dx.doi.org/10.3389/fphar.2022.794931

Ejemplares similares

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
por: Ye, Zhize, et al.
Publicado: (2022)

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions
por: Kong, Qihui, et al.
Publicado: (2023)

Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis
por: Zhao, Xianghong, et al.
Publicado: (2022)

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
por: Majam, Teerapat, et al.
Publicado: (2023)

Proton Pump Inhibitors and Cancer: Current State of Play
por: Bridoux, Marie, et al.
Publicado: (2022)

Proton Pump Inhibitors in IPF: A Call for Clinical Trials
por: Ghebre, Yohannes T.
Publicado: (2018)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
por: Seah, Sherry, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells
por: Chueca, Eduardo, et al.
Publicado: (2016)

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
por: Ikemura, Kenji, et al.
Publicado: (2017)

Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes
por: Lazzerini, Pietro E., et al.
Publicado: (2018)

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan
por: Cheng, Kao-Chi, et al.
Publicado: (2017)

Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics
por: Matuz, Mária, et al.
Publicado: (2020)

Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study
por: Wang, Yao-Tung, et al.
Publicado: (2020)

Clinical Intervention Increases Rational Use of Proton Pump Inhibitors in the General Surgery Department
por: Chen, Qiying, et al.
Publicado: (2022)

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
por: Tian, Liang, et al.
Publicado: (2023)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study
por: Peng, Yen-Chun, et al.
Publicado: (2018)

When does proton pump inhibitor treatment become long term? A scoping review
por: Haastrup, Peter Fentz, et al.
Publicado: (2021)

A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia
por: Trenaman, Shanna C., et al.
Publicado: (2022)

Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations
por: Betari, Nibal, et al.
Publicado: (2020)

The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study
por: Shafrir, Asher, et al.
Publicado: (2022)

Proton Pump Inhibitors Were Associated With Reduced Pseudocysts in Acute Pancreatitis: A Multicenter Cohort Study
por: Zhang, Shengyu, et al.
Publicado: (2021)

Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis
por: Guo, Huizhu, et al.
Publicado: (2023)

Evaluating physicians’ awareness and prescribing trends regarding proton pump inhibitors: a cross-sectional study
por: Swed, Sarya, et al.
Publicado: (2023)

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
por: Sychev, DA, et al.
Publicado: (2015)

Antifibrotic Effect of a Novel Selective 11β-HSD2 Inhibitor (WZ51) in a rat Model of Myocardial Fibrosis
por: Zhuang, Fei, et al.
Publicado: (2021)

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study
por: Yuan, Zheng, et al.
Publicado: (2022)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real‐Life: Retrospective Cohort Study
por: Gronich, Naomi, et al.
Publicado: (2022)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis
por: Guo, Hongzhou, et al.
Publicado: (2021)

Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis
por: Zhou, Wence, et al.
Publicado: (2022)

Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
por: Lin, Wan-Ying, et al.
Publicado: (2022)

Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents
por: Kakiuchi, Toshihiko
Publicado: (2023)

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
por: Kabir, Md, et al.
Publicado: (2022)

Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis
por: Zheng, Zeyi, et al.
Publicado: (2023)

Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis
por: Morino, Yuko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_veke9hqlq7c1nf4mb4d9ovo24c